Beam Therapeutics (BEAM) FCF Margin (2019 - 2026)
Beam Therapeutics (BEAM) reported FCF Margin of 411.95% for Q1 2026, up 99821.0% year-over-year from N/an in Q1 2025, and down 477.24% quarter-over-quarter from 71.37% in Q4 2025.
Beam Therapeutics (BEAM) FCF Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of FCF Margin data on file, last reported at 411.95% in Q1 2026.
- FCF Margin for Q1 2026 came in at 411.95%, up 99821.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 226.68% (up 32904.0% YoY), and the FY2025 annual result was 247.86%, up 30014.0% from the prior year.
- FCF Margin retreated to 411.95% in Q1 2026 per BEAM's latest filing, from 71.37% in the prior quarter.
- Over five years, FCF Margin peaked at 2505.11% in Q1 2022 and troughed at 1410.16% in Q1 2025.
- A 5-year average of 408.15% and a median of 497.73% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin surged 83677178 bps in 2022, then plunged 300284 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 561.38% in 2022, then soared by 107 bps to 41.58% in 2023, then slumped by 670 bps to 236.88% in 2024, then surged by 70 bps to 71.37% in 2025, then sank by 477 bps to 411.95% in 2026.
- Business Quant data shows BEAM's FCF Margin at 411.95% in Q1 2026, 71.37% in Q4 2025, and 808.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -411.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -411.95% |
| Dec 31, 2025 | -71.37% |
| Sep 30, 2025 | -808.46% |
| Jun 30, 2025 | -959.08% |
| Mar 31, 2025 | -1,410.16% |
| Dec 31, 2024 | -236.88% |
| Sep 30, 2024 | -655.83% |
| Jun 30, 2024 | -706.52% |
| Mar 31, 2024 | -1,350.94% |
| Dec 31, 2023 | 41.58% |
| Sep 30, 2023 | -568.44% |
| Jun 30, 2023 | -478.17% |
| Mar 31, 2023 | -497.73% |
| Dec 31, 2022 | -561.38% |
| Sep 30, 2022 | -324.39% |
| Jun 30, 2022 | -443.91% |
| Mar 31, 2022 | 2,505.11% |
| Dec 31, 2021 | 50.93% |
| Sep 30, 2021 | -3,408.26% |
| Jun 30, 2021 | -424,650.00% |